Myokardia Inc (NASDAQ:MYOK) CEO Anastasios Gianakakos Sells 5,000 Shares

Myokardia Inc (NASDAQ:MYOK) CEO Anastasios Gianakakos sold 5,000 shares of the company’s stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $75.39, for a total value of $376,950.00. Following the completion of the sale, the chief executive officer now directly owns 91,777 shares of the company’s stock, valued at approximately $6,919,068.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Anastasios Gianakakos also recently made the following trade(s):

  • On Monday, January 6th, Anastasios Gianakakos sold 12,687 shares of Myokardia stock. The stock was sold at an average price of $68.45, for a total value of $868,425.15.
  • On Friday, January 3rd, Anastasios Gianakakos sold 5,000 shares of Myokardia stock. The stock was sold at an average price of $71.80, for a total value of $359,000.00.
  • On Monday, December 2nd, Anastasios Gianakakos sold 5,000 shares of Myokardia stock. The stock was sold at an average price of $65.02, for a total value of $325,100.00.
  • On Monday, November 4th, Anastasios Gianakakos sold 5,000 shares of Myokardia stock. The stock was sold at an average price of $59.07, for a total value of $295,350.00.

NASDAQ MYOK traded up $4.39 on Tuesday, hitting $76.77. 395,764 shares of the stock traded hands, compared to its average volume of 388,888. The stock has a 50-day moving average of $69.41 and a 200 day moving average of $58.13. Myokardia Inc has a twelve month low of $39.01 and a twelve month high of $76.97. The company has a market capitalization of $3.37 billion, a P/E ratio of -43.62 and a beta of 2.07.

Myokardia (NASDAQ:MYOK) last announced its quarterly earnings data on Monday, November 11th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.91) by $0.57. Research analysts expect that Myokardia Inc will post -5.03 earnings per share for the current year.

Several equities research analysts have recently weighed in on the company. BidaskClub downgraded Myokardia from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 7th. Maxim Group reaffirmed an “average” rating on shares of Myokardia in a research report on Monday, October 28th. Cowen reaffirmed a “buy” rating and issued a $73.00 target price on shares of Myokardia in a research report on Monday, November 11th. Guggenheim assumed coverage on Myokardia in a research report on Thursday, September 19th. They issued a “buy” rating for the company. Finally, Citigroup upped their target price on Myokardia from $70.00 to $87.00 and gave the stock a “buy” rating in a research report on Friday, December 20th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Myokardia currently has a consensus rating of “Buy” and an average target price of $80.25.

Institutional investors have recently made changes to their positions in the company. Quadrant Capital Group LLC acquired a new stake in shares of Myokardia during the 3rd quarter worth approximately $33,000. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Myokardia during the 1st quarter worth approximately $68,000. Strs Ohio raised its position in shares of Myokardia by 440.0% during the 3rd quarter. Strs Ohio now owns 2,700 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 2,200 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Myokardia by 20.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,382 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 579 shares during the period. Finally, NJ State Employees Deferred Compensation Plan acquired a new stake in shares of Myokardia during the 3rd quarter worth approximately $209,000.

Myokardia Company Profile

MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.

Featured Story: Purposes and Functions of the Federal Reserve

Insider Buying and Selling by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.